JP2015504924A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504924A5
JP2015504924A5 JP2014554892A JP2014554892A JP2015504924A5 JP 2015504924 A5 JP2015504924 A5 JP 2015504924A5 JP 2014554892 A JP2014554892 A JP 2014554892A JP 2014554892 A JP2014554892 A JP 2014554892A JP 2015504924 A5 JP2015504924 A5 JP 2015504924A5
Authority
JP
Japan
Prior art keywords
progesterone
drug substance
transdermal pharmaceutical
transdermal
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014554892A
Other languages
English (en)
Japanese (ja)
Other versions
JP6342334B2 (ja
JP2015504924A (ja
Filing date
Publication date
Priority claimed from US13/684,002 external-priority patent/US8633178B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/023309 external-priority patent/WO2013112947A1/en
Publication of JP2015504924A publication Critical patent/JP2015504924A/ja
Publication of JP2015504924A5 publication Critical patent/JP2015504924A5/ja
Application granted granted Critical
Publication of JP6342334B2 publication Critical patent/JP6342334B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014554892A 2012-01-26 2013-01-25 経皮ホルモン補充療法 Expired - Fee Related JP6342334B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261590927P 2012-01-26 2012-01-26
US61/590,927 2012-01-26
US201261661302P 2012-06-18 2012-06-18
US61/661,302 2012-06-18
US201261662265P 2012-06-20 2012-06-20
US61/662,265 2012-06-20
US13/684,002 2012-11-21
US13/684,002 US8633178B2 (en) 2011-11-23 2012-11-21 Natural combination hormone replacement formulations and therapies
PCT/US2013/023309 WO2013112947A1 (en) 2012-01-26 2013-01-25 Transdermal hormone replacement therapies

Publications (3)

Publication Number Publication Date
JP2015504924A JP2015504924A (ja) 2015-02-16
JP2015504924A5 true JP2015504924A5 (OSRAM) 2016-03-10
JP6342334B2 JP6342334B2 (ja) 2018-06-13

Family

ID=48873981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014554892A Expired - Fee Related JP6342334B2 (ja) 2012-01-26 2013-01-25 経皮ホルモン補充療法

Country Status (7)

Country Link
EP (1) EP2806742B1 (OSRAM)
JP (1) JP6342334B2 (OSRAM)
AU (1) AU2013211876B2 (OSRAM)
BR (1) BR112014018439A8 (OSRAM)
CA (1) CA2861346C (OSRAM)
MX (1) MX367596B (OSRAM)
WO (1) WO2013112947A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015073177A1 (en) * 2013-10-10 2015-05-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
BR112016009008B8 (pt) * 2013-10-22 2023-01-31 Therapeuticsmd Inc Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
AU2015296609A1 (en) * 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US20230414912A1 (en) * 2020-11-12 2023-12-28 Medrx Co., Ltd. Microneedle Array Coated with Composition Containing Particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
JP2910857B2 (ja) * 1989-04-04 1999-06-23 ニチバン株式会社 プロスタグランジンe1経皮吸収製剤
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
AU3136897A (en) * 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
KR20030003769A (ko) * 2000-05-31 2003-01-10 니찌방 가부시기가이샤 경피흡수형 스테로이드 외용제
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

Similar Documents

Publication Publication Date Title
JP2015504924A5 (OSRAM)
EP2861233B1 (en) Transdermal hormone replacement therapies
KR102177782B1 (ko) 천연 병용 호르몬 대체 제형 및 요법
KR101607034B1 (ko) 경구 테스토스테론 에스테르 제형 및 이를 포함하는 테스토스테론 결핍을 치료하는 방법
JP2015520237A5 (OSRAM)
ES2885523T3 (es) Formulaciones y terapias de reposición hormonal de combinación naturales
JP6342334B2 (ja) 経皮ホルモン補充療法
JP2015520235A5 (OSRAM)
US20170281646A1 (en) Steroid hormone pharmaceutical composition
JP2007508296A5 (OSRAM)
JP2012527484A (ja) 哺乳動物疾患の治療におけるエンドキシフェンの方法および組成物
AU2014261009A1 (en) Compositions of pharmaceutical actives containing Diethylene glycol monoethyl ether or other alkyl derivatives
JP2017516768A (ja) 天然の併用ホルモン補充療法剤及び療法
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2016503030A5 (OSRAM)
JP2020503269A (ja) 経口ウンデカン酸テストステロン療法
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
HRP20140204T1 (hr) Oralni oblici doziranja bendamustina
JP2022517217A (ja) 経口薄フィルム
JP2017516794A (ja) 経口イソトレチノイン医薬組成物
CN104363899A (zh) [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的增溶的胶囊制剂
MX384683B (es) Composición y métodos farmacéuticos.
JP2019523779A5 (OSRAM)
JP2011507853A5 (OSRAM)
CN105073118A (zh) 用于经口递送的脂平衡长链睾酮酯